Clinical studies evaluating outcomes of patients undergoing total joint replacement surgery have demonstrated that the combination of reducing the hospital length of stay (LOS), discharging patients directly to home and strict monitoring, starting at hospitalization and continuing up to 90 days after discharge, are powerful practices that can significantly reduce readmissions rates and costs and improve quality of patient care. Over the last three decades there has been a steady trend toward reduction in LOS prior to discharge, which is currently less than three days. Under new guidelines, hospitals may be charged significant fees for readmissions during the 90-day post-discharge period, and consistent follow-up has become increasingly important in determining final clinical and economic outcomes.
The new technology will enable Activecare Online to report key patient health and risk indicators to a secure, HIPAA compliant cloud-based storage system using Bluetooth and a smartphone app. Authorized caregivers will be able to continuously monitor and review a patient’s status with a specialized dashboard to determine if additional treatment is needed. Additionally, providers will be able to directly communicate with patients through text messaging.
“By adding new monitoring and communications capabilities to our Activecare platform, we expect to simultaneously improve patient outcomes and reduce hospital costs,” said Timothy A. McCarthy, CEO of MCS. “We predict our system’s close post-surgical surveillance will decrease hospital readmissions, and we are committed to providing daily treatment guidance through the Activecare Online and the new Activecare Customer Care Center. In addition to outcome improvements and cost reductions, we also anticipate better institutional quality metrics following the adoption of our technology.”
MCS has filed for 501(k) clearance from the U.S. Food and Drug Administration and expects to launch Activecare Online in the second half of 2016.
“An established body of scientific evidence has confirmed that prophylactic treatment with mobile compression combined with aspirin chemoprophylaxis following total joint replacement can reduce the occurrence of venous thromboembolism and decrease adverse events, infections and bleeding complications in standard risk patients,” said Richard Iorio, M.D., an orthopedic surgeon in New York. “The next generation Activecare System improves on existing technology by improving connectivity between the patient, hospital and physician, which has the potential to improve clinical outcomes and reduce costs to the healthcare system.”
Venous thromboembolism (VTE), the most common complication following total joint replacement procedures, includes both deep vein thrombosis (DVT), a blood clot in a deep vein in the lower extremities, and pulmonary embolism (PE), where the blood clot becomes dislodged and migrates to the lungs. In the United States and the United Kingdom, VTEs kill more people than AIDS, breast cancer, prostate cancer and traffic accidents combined.